Cytek Biosciences, Inc.
CTKB
$4.11
-$0.065-1.56%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 262.02M | 265.61M | 277.86M | 277.78M | 277.21M |
| Total Receivables | 56.67M | 55.21M | 60.59M | 52.66M | 44.75M |
| Inventory | 49.94M | 45.65M | 44.01M | 46.86M | 50.12M |
| Prepaid Expenses | 4.03M | 4.37M | 4.64M | 3.15M | 2.80M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 10.17M | 9.67M | 9.35M | 9.76M | 9.20M |
| Total Current Assets | 382.83M | 380.50M | 396.45M | 390.19M | 384.08M |
|
|
|||||
| Total Current Assets | 382.83M | 380.50M | 396.45M | 390.19M | 384.08M |
| Net Property, Plant & Equipment | 34.74M | 27.70M | 28.13M | 28.63M | 27.44M |
| Long-term Investments | 16.71M | 16.68M | 16.66M | 16.18M | 16.18M |
| Goodwill | 16.71M | 16.68M | 16.66M | 16.18M | 16.18M |
| Total Other Intangibles | 18.60M | 19.43M | 20.13M | 20.49M | 21.42M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 38.85M | 36.68M | 36.53M | 34.13M | 34.60M |
| Total Assets | 493.32M | 482.60M | 499.50M | 491.23M | 483.73M |
|
|
|||||
| Total Accounts Payable | 6.85M | 6.25M | 5.53M | 5.39M | 3.19M |
| Total Accrued Expenses | 22.12M | 19.75M | 21.69M | 20.12M | 14.38M |
| Short-term Debt | 1.40M | 2.40M | 4.16M | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 7.37M | 5.13M | 4.26M | 5.53M | 4.33M |
| Total Finance Division Other Current Liabilities | 35.53M | 34.16M | 32.03M | 31.76M | 30.48M |
| Total Other Current Liabilities | 35.53M | 34.16M | 32.03M | 31.76M | 30.48M |
| Total Current Liabilities | 73.27M | 67.69M | 67.66M | 62.80M | 52.38M |
|
|
|||||
| Total Current Liabilities | 73.27M | 67.69M | 67.66M | 62.80M | 52.38M |
| Long-Term Debt | 791.00K | 918.00K | 1.05M | 1.24M | 1.33M |
| Short-term Debt | 1.40M | 2.40M | 4.16M | -- | -- |
| Capital Leases | 14.12M | 7.45M | 7.55M | 7.76M | 8.11M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 27.58M | 26.92M | 27.50M | 33.97M | 32.78M |
| Total Liabilities | 115.76M | 102.97M | 103.76M | 105.76M | 94.60M |
|
|
|||||
| Common Stock & APIC | 429.78M | 426.83M | 430.92M | 430.20M | 435.10M |
| Retained Earnings | -52.18M | -46.60M | -35.20M | -44.84M | -45.78M |
| Treasury Stock & Other | -38.00K | -609.00K | 16.00K | 101.00K | -195.00K |
| Total Common Equity | 377.56M | 379.62M | 395.74M | 385.46M | 389.12M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 377.56M | 379.62M | 395.74M | 385.46M | 389.12M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 377.56M | 379.62M | 395.74M | 385.46M | 389.12M |
|
|
|||||